Hepatic steatosis in HIV-HCV coinfected patients: Analysis of risk factors

AIDS

Volumn 20, Issue 4, 2006, Pages 525-531

  Bani Sadr, Firouzé ^a,f   Carrat, Fabrice ^a   Bedossa, Pierre ^b   Piroth, Lionel ^c   Cacoub, Patrice ^d   Perronne, Christian ^e   Degott, Claude ^b   Pol, Stanislas ^b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e RAYMOND POINCARÉ HOSPITAL   (France)

^f HÔPITAL SAINT ANTOINE   (France)

Author keywords

Antiretroviral therapy; Body mass index; Fibrosis; Genotype 3; HCV viral load

Indexed keywords

ANTIRETROVIRUS AGENT; FERRITIN; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; MESSENGER RNA; VIRUS RNA;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; VIRUS LOAD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETICS; LIVER CIRRHOSIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RNA, MESSENGER; RNA, VIRAL; VIRAL LOAD;

EID: 33645421568     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000210606.63138.f5     Document Type: Article

References (33)

1. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25:735-739.
2. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:1358-1364.
3. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29:1215-1219.
4. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40:484-490.
5. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37:837-842.
6. Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004; 11:455-458.
7. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31:162-166.
8. Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, Schmutz G, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39:311-317.
9. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276:37514-37519.
10. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b versus standard interferon alfa-2b, plus ribavirin for chronic hepatitis C in HIV-infected patients. Randomized controlled trial. JAMA 2004; 292:2839-2848.
11. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
12. Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C, Powell EE. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001; 34:314-320.
13. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004; 24:399-413.
14. Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192:1943-1949.
15. Sharma P, Balan V, Hernandez J, Rosati M, Williams J, Rodriguez-Luna H, et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci 2004; 49:25-29.
16. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51:89-94.
17. Tien PC, Grunfeld C. The fatty liver in AIDS. Semin Gastrointest Dis 2002; 13:47-54.
18. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005; 42:310-316.
19. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-592.
20. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19:221-240.
21. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78:1527-1531.
22. Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53:420-424.
23. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005; 41:82-87.
24. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97:2408-2414.
25. Fernandez-Rodriguez CM, Gutierrez ML, Serrano PL, Lledo JL, Santander C, Fernandez TP, et al. Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci 2004; 49:1971-1976.
26. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38:128-133.
27. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356-1362.
28. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39:179-187.
29. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96:2448-2455.
30. Serfaty L, Poujol-Robert A, Carbonell N, Chazouilleres O, Poupon RE, Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002; 97:1807-1812.
31. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002; 282:G193-G199.
32. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387-1395.
33. Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, Terrault NA. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41:372-379.